Galectin Therapeutics Inc (GALT)
2.06
-0.09
(-4.19%)
USD |
NASDAQ |
Jul 05, 16:00
2.05
-0.01
(-0.49%)
After-Hours: 20:00
Galectin Therapeutics Research and Development Expense (Annual): 32.13M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 32.13M |
December 31, 2022 | 31.74M |
December 31, 2021 | 23.82M |
December 31, 2020 | 17.98M |
December 31, 2019 | 7.467M |
December 31, 2018 | 6.471M |
December 31, 2017 | 11.72M |
December 31, 2016 | 15.32M |
December 31, 2015 | 13.11M |
December 31, 2014 | 8.425M |
December 31, 2013 | 5.688M |
December 31, 2012 | 4.527M |
Date | Value |
---|---|
December 31, 2011 | 3.552M |
December 31, 2010 | 1.066M |
December 31, 2009 | 1.11M |
December 31, 2008 | 1.774M |
December 31, 2007 | 2.053M |
December 31, 2006 | 3.019M |
December 31, 2005 | 3.04M |
December 31, 2004 | 3.042M |
December 31, 2003 | 1.95M |
December 31, 2002 | 1.483M |
December 31, 2001 | 0.8935M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
7.467M
Minimum
2019
32.13M
Maximum
2023
22.63M
Average
23.82M
Median
2021
Research and Development Expense (Annual) Benchmarks
Intuitive Surgical Inc | 998.80M |
Palatin Technologies Inc | 22.63M |
Adial Pharmaceuticals Inc | 1.267M |
Benitec Biopharma Inc | 12.77M |
Outset Medical Inc | 57.31M |